EVP, Preclinical Sciences
Atea Pharmaceuticals, Inc.
Steve Good holds an M.S. degree in biochemistry from the University of Wisconsin and a B.S. in chemistry and biology from Grinnell College. He has extensive expertise in drug discovery and development, with over 40 years of experience in the pharmaceutical industry and with over 60 publications and conference presentations. Currently Steve is Executive Vice-president of Preclinical Sciences at Atea Pharmaceuticals in Boston and has been with Atea since its inception in 2013. Previously Steve has held various senior management positions at Idenix Pharmaceuticals and AstraZeneca, after spending 26 years at GlaxoSmithKline and its predecessors GlaxoWellcome and BurroughsWellcome. Steve began his pharmaceutical career contributing to the discovery and development of several antiviral medicines including acyclovir, valacyclovir, zidovudine and abacavir and has now come full circle as his current company is focused on rapidly advancing transformative therapies for patients with severe viral diseases.
Disclosure: Atea Pharmaceuticals, Inc. (Individual(s) Involved: Self): Employee